Julia Rotow, MD

home / authors / julia-rotow-md

Julia Rotow, MD, discusses remaining questions with brigatinib in ALK-positive non–small cell lung cancer.

Julia Rotow, MD, discusses the implications of next-generation ALK inhibitors in non–small cell lung cancer.

Julia Rotow, MD, discusses the utility of brigatinib versus crizotinib for the first-line treatment of patients with ALK-positive non

Julia Rotow, MD, discusses updated data from the phase III ALEX trial in ALK-positive non–small cell lung cancer.

Julia Rotow, MD, discusses the safety profile of brigatinib in ALK-positive non–small cell lung cancer.

in Genitourinary, Gastrointestinal, and Breast Cancers, Plus Sarcoma and Melanoma at ASCO 2023: Drs Rini, Lewis, Trent, Luke, Kunz, and Lustberg

ZUMA-7 Primary OS Analysis Supports Use of Axi-cel As Second-line SOC in R/R LBCL

Sintilimab Plus Chemoradiotherapy Improves EFS in Locally Advanced Nasopharyngeal Carcinoma

Sacituzumab Govitecan Displays OS Benefit in Pretreated HR+/HER2– Breast Cancer

Contact Info

2 Clarke Drive
Cranbury, NJ 08512